ArticleInflammation2026
Machine Learning Identifies Key Cells and Therapeutic Targets in Intervertebral Disc Degeneration: SASP-Driven Matrix Catabolism, Inflammation Amplification, and Metabolic Collapse.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mechanotransduction in intervertebral disc degeneration: from compartment-specific sensors to translational frontiers.Frontiers in bioengineering and biotechnology · 2026Review
- Plastrum Testudinis Extract Ameliorates Intervertebral Disc Degeneration by Suppressing NF-κB Mediated Senescence and Inflammation.Journal of immunology research · 2026Article
- Senescence-associated secretory phenotype: the "pathogenic" factor driving orthopedic degenerative diseases and its regulation.Frontiers in aging · 2026Review
- Mechanism-guided biomaterial strategies for intervertebral disc degeneration: Pathological heterogeneity, functional classification, and translational perspectives.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Intervertebral disc degeneration (IVDD) is a major contributor to low back pain, yet its cellular and molecular mechanisms remain incompletely understood. In this study, we integrated single-cell and bulk transcriptomic data to uncover the role of senescence-associated secretory phenotype (SASP) signaling in IVDD progression. Single-cell RNA sequencing delineated the heterogeneity of nucleus pulposus cells (NPCs) subtypes and revealed significant differences in senescence levels and SASP activity. Bulk RNA-seq integration across multiple datasets further confirmed widespread SASP activation and defined a core regulatory network centered on Bone Morphogenetic Protein 2 (BMP2) and Matrix Metalloproteinase 3 (MMP3), identified via WGCNA and machine learning algorithms (LASSO, Random Forest, Boruta). A SASP scoring model based on these two genes showed strong diagnostic performance. Drug screening identified Simvastatin as a high-affinity dual inhibitor of BMP2/MMP3, with molecular docking supporting its therapeutic potential. In vitro, Simvastatin treatment reduced NPCs senescence and apoptosis, while in vivo studies demonstrated that Simvastatin preserved disc structure, decreased pro-inflammatory cytokine levels, and mitigated degenerative changes in a murine IVDD model. Collectively, this study establishes a regulatory framework of SASP in IVDD and proposes BMP2/MMP3 as promising targets for intervention. Our findings offer insights and a potential translational path for slowing disc degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.